Immunovaccine’s DepoVax to be used in vaccine trial for HNC
Immunovaccine, a clinical-stage vaccine company, announced that its DepoVax adjuvanting technology will underlie the design of a new cancer vaccine trial for the treatment of head and neck cancer (HNC). The Dana-Farber Cancer Institute in Boston has received a $1.2 million research grant for the clinical evaluation of DepoVax, according to the company. The three-year grant will be used to fund a phase I clinical trial of the group’s peptide


